Management of advanced prostate cancer in elderly patients

被引：0
作者：
Bompas, Emmanuelle [1 ]
Dedecker, Laure
机构：
[1] ICO, Ctr Rene Gauducheau, Med Oncol Serv, F-44405 Nantes, France
来源：
BULLETIN DU CANCER | 2012年 / 99卷
关键词：
older; cancer; prostate; CGA; ANDROGEN-DEPRIVATION THERAPY; MITOXANTRONE PLUS PREDNISONE; COMPREHENSIVE GERIATRIC ASSESSMENT; DOCETAXEL-BASED CHEMOTHERAPY; RANDOMIZED PHASE-II; CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; BREAST-CANCER; INTERNATIONAL-SOCIETY; OLDER PATIENTS;
D O I：
10.1684/bdc.2012.1561
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With the increase of the senior demographic, an increase in cancer including prostate cancer has been seen. The challenge is to offer personalized cancer care because of population specificity. The only way is to share two experiences: the oncologist's experience who knows prostate cancer, prognosis and adverses effects of treatments and geriatrician's experience who consider old patients in their entirety thanks to comprehensive geriatric assessment (CGA). This article provides data about treatments of prostate cancer and geriatric evaluation to demonstrate the importance to work together for a "tailored" care.
引用
收藏
页码：S21 / S29
页数：9
相关论文
共 87 条
  • [1] Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
    Alibhai, Shabbir M. H.
    Duong-Hua, Minh
    Sutradhar, Rinku
    Fleshner, Neil E.
    Warde, Padraig
    Cheung, Angela M.
    Paszat, Lawrence F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3452 - 3458
  • [2] ESPEN guidelines on enteral nutrition:: Non-surgical oncology
    Arends, J.
    Bodoky, G.
    Bozzetti, F.
    Fearon, K.
    Muscaritoli, M.
    Selga, G.
    van Bokhorst-de van der Schuereng, M. A. E.
    von Meyenfeldt, M.
    Zuercher, G.
    Fietkau, R.
    Aulbert, E.
    Frick, B.
    Holm, M.
    Kneba, M.
    Mestrom, H. J.
    Zander, A.
    [J]. CLINICAL NUTRITION, 2006, 25 (02) : 245 - 259
  • [3] Arias E., 2007, NATL VITAL STAT REPO, V54
  • [4] A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth S.
    Yang, Yi-Chun Ou
    de Wit, Ronald
    Tannock, Ian F.
    Eisenberger, Mario
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (21) : 6396 - 6403
  • [5] The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
    Armstrong, Andrew J.
    Tannock, Ian F.
    de Wit, Ronald
    George, Daniel J.
    Eisenberger, Mario
    Halabi, Susan
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (03) : 517 - 525
  • [6] Preoperative assessment of surgical risk in oncogeriatric patients
    Audisio, RA
    Ramesh, H
    Longo, WE
    Zbar, AP
    Pope, D
    [J]. ONCOLOGIST, 2005, 10 (04) : 262 - 268
  • [7] Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224
  • [8] Beer Tomasz M, 2003, Clin Prostate Cancer, V2, P167, DOI 10.3816/CGC.2003.n.025
  • [9] Variations in morbidity after radical prostatectomy.
    Begg, CB
    Riedel, ER
    Bach, PB
    Kattan, MW
    Schrag, D
    Warren, JL
    Scardino, PT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) : 1138 - 1144
  • [10] Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer
    Berry, W
    Dakhil, S
    Modiano, M
    Gregurich, M
    Asmar, L
    [J]. JOURNAL OF UROLOGY, 2002, 168 (06) : 2439 - 2443
123456789